Objective-To compare responses of patients with cancer with those of a matched control group, cancer specialists, general practitioners, and cancer nurses in assessing personal cost-benefit of chemotherapy.
Introduction
Until fairly recently the general public expected, and indeed was happy, to leave medical decision making to doctors. An increasing interest in consumer affairs has resulted in an awareness that personal responsibility for health care and participation in medical decision making are desirable and possible. Several North American studies have examined participation preferences. Cassileth et al sought the preferences of 256 patients with cancer.' Most patients in each age group preferred active participation, although, generally, younger patients wanted to be more involved. Degner and Russell asked 60 patients with cancer whether they preferred to "keep, share, or give away" control over decision making.) Most preferred the option of shared control, usually with the doctor rather than a relative.
Increased participation in decision making means that patients need more information about their disease and treatment options. This has caused concern among health care workers, who thought that this might be depressing for patients. ' Cassileth et al found that patients were able to maintain hope, and in fact were generally more hopeful, despite having this information. ' Faden et 
Subjects and Methods

QUESTIONNAIRE
We used a questionnaire describing two hypothetical treatments with chemotherapy: one representing a BMJ VOLUME 300 typical intensive chemotherapy regimen and the other a much milder chemotherapy regimen. The intensive regimen was said to have a considerable number of side effects and drawbacks, such as severe nausea and vomiting, hair loss, frequent use of needles and drips, frequent tiredness and weakness, admission to hospital for three or four days a month, decreased sexual interest (for the period of treatment), and possible infertility. The mild regimen was said to have fewer side effects and drawbacks, with only slight nausea and vomiting, no loss of hair, occasional use of needles and drips, some tiredness and weakness, and admission to hospital about once a month.
Subjects were asked to assess their willingness to have these two treatments in three possible circumstances; the first when the treatment offered a chance of cure, the second when cure was not possible but the treatment offered the chance of prolonging life, and the third when treatment was given only to relieve symptoms.
Patients were asked to rate the possible benefit that would make acceptance of these treatments worth while. Thus for the curative treatment they rated what chance of cure between 1% and 100% would make the treatment worth while. For the treatment designed to prolong life they were asked what duration, ranging from three months to five years, would make this treatment worth while, and when the treatment was given to relieve symptoms they were asked tvhat chance of relieving symptoms, rated from 1% to 100%, would make this treatment worth while. In all circumstances there was an option for saying that the treatment was unacceptable under any circumstances.
SUBJECTS
Patients-One hundred and six consecutive patients with solid tumours who were about to receive chemotherapy were asked to complete the questionnaire. Six patients were unable to complete it, three being too distressed and three being unable to understand the questions. Of the 100 patients remaining, 41 had small cell carcinoma of the lung and 59 had other types of tumour including ovarian carcinoma, cervical carcinoma, myeloma, and lymphoma. The median age of the patients was 60 (range 23 to 80), and there was no significant difference in age between men and women. The questionnaire was given to patients by a research nurse, who made it clear that she had no part in decisions about their treatment. It was given a second time to half of the patients chosen randomly after they had completed three cycles of treatment. Two patients who were approached thought that they could not repeat the questionnaire because their treatment with chemotherapy had failed and they were too distressed to consider a hypothetical situation.
Controls-One hundred controls matched for age, sex, ethnic origin, and occupation were obtained from the community. None of them or close members of their families had cancer or had previously had cancer.
Patients with other diseases and hospital staff who had General practitioners-A direct postal company circulated the questionnaire to 1500 randomly chosen general practitioners. The company advised us that this would probably produce 100 responses, but in fact 790 (53%) general practitioners responded.
Cancer nurses-Questionnaires were circulated randomly to 1000 of the 3500 members of the Royal College of Nursing Oncology Nursing Society, and 303 (30%) responded.
Differences in proportions of subjects opting for each preference among the different groups were tested for significance using the x2 test. Median scores were produced for each group as a summary statistic.
Results Table I shows the median scores for each group for the intensive and mild treatments. The scores represented the minimal benefit that would make treatment acceptable to the subjects, the range for all groups being from the minimum acceptable to unacceptable.
Substantial differences were shown between the patients who had cancer and every other group. Most importantly, the patients with cancer gave very different results from the matched control group for both treatments in all circumstances. In general, the patients were most likely to accept intensive treatments for a potentially small benefit whereas the control group were least likely to accept intensive treatment and wanted the most benefit for any particular risk. After completing three months of treatment the responses of the 50 patients who completed the questionnaire a second time changed negligibly. No significant difference was shown when the first and second responses were compared for the intensive and the mild treatments, whether or not the patient had actually received an intensive or a milder treatment.
The responses of the medical oncologists, general practitioners, and cancer nurses fell between those of the patients and controls, with medical oncologists being more likely to accept radical treatments than general practitioners, who in turn were more likely to accept them than cancer nurses. Radiotherapists were the least likely of any group to accept treatment. Table II shows the percentage of subjects in each group who would accept the intensive and mild treatments given minimal benefit for each category for cure, prolonging life, or relief of symptoms. It illustrates the dramatic difference between the patients and all other groups. Significantly more patients accepted treatments with much less benefit than any other group (p<0001), and the radiotherapists required more benefit from the treatments than any other group (p<0-01).
Discussion
Presenting patients with treatment options is a complex and difficult process. On the one hand patients need sufficient information to allow them to make an informed decision, but on the other hand the doctor does not want to remove all hope and demoralise the patient. Thus most patients treated in a centre that specialises in the treatment of cancer are given infor-BMJ VOLUME 300 
